SCHEMBL3417238

SCHEMBL3417238

CCN(c1ccc(C(F)(F)F)cc1)c1ccc(O)c(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ RECQL P46063 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ EGFR P00533 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ RXRA P19793 2/20 0.42
▸ RXRB P28702 2/20 0.42
▸ RXRG P48443 2/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ HSP90AB1 P08238 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CSNK2A1 P68400 1/20 0.41
▸ MCL1 Q07820 3/20 0.40
▸ BCL2L1 Q07817 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116150 0.99 MEN1 (0.45) MEN1KMT2ARECQLALDH1A1HPGD
Potassium Ion SCHEMBL4798604 0.87 HSP90AA1 (0.40) MEN1KMT2ARXRARXRBRXRG
SCHEMBL4463291 0.85 P2RX1 (0.39) MEN1KMT2AHSP90AA1HSP90AB1P2RX1
SCHEMBL1520808 0.78 MEN1 (0.61) MEN1KMT2ARECQLALDH1A1HPGD
SCHEMBL13618923 0.77 PTPN11 (0.45) MEN1KMT2ARECQLALDH1A1HPGD
SCHEMBL130628 0.76 ALDH1A1 (0.59) MEN1KMT2ARECQLALDH1A1HPGD
SCHEMBL5512932 0.74 ALDH1A1 (0.48) ALDH1A1MAPT
SCHEMBL10786191 0.74 ALDH1A1 (0.58) MEN1KMT2ARECQLALDH1A1HPGD
SCHEMBL330660 0.73 ACMSD (0.66) MEN1KMT2ARECQLALDH1A1HPGD
SCHEMBL12656096 0.73 PTPN11 (0.66) ALDH1A1MCL1BCL2L1KDM4EKAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216749-A1 Combination Therapy for Neuroprotection S.H. PHARMA., LTD (KR) 2010-08-26 — — US claimed
EP-2004164-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2018-08-08 — — EP disclosed
US-8598383-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-12-03 — — US disclosed
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2013-11-28 — — US disclosed
US-8455470-B2 Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases NEUROTECH PHARMACEUTICALS CO., LTD (KR) 2013-06-04 — — US disclosed
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GWAG BYOUNG-JOO (KR) 2012-08-16 — — US disclosed
US-20100216749-A1 Combination Therapy for Neuroprotection S.H. PHARMA., LTD (KR) 2010-08-26 — — US disclosed
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases GNT PHARMA CO., LTD. (KR) 2009-11-12 — — US disclosed
US-20090240079-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2009-09-24 — — US disclosed
WO-2009045083-A2 COMBINATION THERAPY FOR NEUROPROTECTION S.H. PHARMA., LTD (KR) 2009-04-09 — — WO disclosed
EP-2004164-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES Neurotech Co., Ltd. (KR) 2008-12-24 — — EP disclosed
WO-2007119973-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES NEUROTECH CO., LTD. (KR) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209025-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B MEN1 4381/4885KMT2A 3791/4885RECQL 4478/4885
US-20090240079-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B MEN1 4381/4885KMT2A 3791/4885RECQL 4478/4885
US-20090281181-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B MEN1 4381/4885KMT2A 3791/4885RECQL 4478/4885
US-20130316988-A1 Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases ALOX12, ALOX15, ALOX15B MEN1 4381/4885KMT2A 3791/4885RECQL 4478/4885
US-20100216749-A1 Combination Therapy for Neuroprotection MPO, BDNF, NLN MEN1 4862/4885KMT2A 2730/4885RECQL 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback